MultiStem Administration for Stroke Treatment and Enhanced Recovery
Research type
Research Study
Full title
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)
IRAS ID
268864
Contact name
Anand Dixit
Contact email
Sponsor organisation
Athersys, Inc.
Eudract number
2019-001680-69
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 9 months, 23 days
Research summary
An ischemic stroke, also commonly called a Cerebrovascular Accident (CVA), happens when the blood flow through the blood vessel(s) supplying your brain is blocked by a clot (group of blood cells that stick together, forming a clump), and no blood and oxygen can reach the affected area in your brain.
This study is evaluating the benefit and potential side effects of an investigational human stem cell product called MultiStem (cell therapy) to treat strokes.
Approximately 300 subjects who have experienced an acute cortical ischemic stroke and fulfill all the eligibility criteria will be enrolled into the study in approximately 60 sites in the world.
This is a Phase 3, randomized, double-blind, placebo-controlled study, menaning neither their participant nor the study doctor will know which medication is being given.
The total study duration for safety follow-up will be 12 months.
REC name
South Central - Oxford A Research Ethics Committee
REC reference
21/SC/0017
Date of REC Opinion
14 Jun 2021
REC opinion
Further Information Favourable Opinion